To evaluate the effects of Cushing syndrome (CS) treatment on serum lipid levels post-treatment.
Key Findings:
CS treatment led to a significant decrease in serum total cholesterol (MD -26.49; 95% CI, -29.95 to -23.04; P < .00001), low-density lipoprotein cholesterol (MD -18.44; 95% CI, -21.30 to -15.57; P < .00001), and triglycerides (MD -17.77; 95% CI, -22.70 to -12.84; P < .00001).
No significant changes were observed in high-density lipoprotein cholesterol levels (MD -2.34; 95% CI, -6.96 to 2.28; P = .32).
Greater decreases in total cholesterol were noted in subjects with adrenal hypercortisolism and those treated with steroidogenesis inhibitors.
Interpretation:
The study demonstrates a significant improvement in serum lipid levels following CS treatment, suggesting potential benefits in managing cardiovascular risks associated with hypercortisolism, which should be considered in clinical practice.
Limitations:
The study included only observational and interventional studies, lacking randomized controlled trials, which limits the strength of the findings.
Variability in definitions and diagnostic criteria for dyslipidemia across studies may affect the results.
Conclusion:
Further studies, particularly randomized controlled trials, are needed to determine if improvements in lipid profiles translate into reduced cardiovascular event risks in patients with Cushing syndrome.
